|
Type |
Publikáció |
| 3 |
Napló |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 36 |
Napló |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 59 |
Napló |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 66 |
Napló |
Avelar MA, Walker SE.
Stability and compatibility of reconstituted hydromorphone with potassium chloride or heparin.
Can J Hosp Pharm 1996 ; 49: 140-145. |
| 73 |
Napló |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Napló |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Napló |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 91 |
Napló |
Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210. |
| 92 |
Napló |
Lee CY, Mauro VF, Alexander KS.
Visual and spectrophotometric determination of compatibility of alteplase and streptokinase with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 606-608. |
| 93 |
Napló |
Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
| 99 |
Napló |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 129 |
Napló |
Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126. |
| 132 |
Napló |
Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184. |
| 150 |
Napló |
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35. |
| 156 |
Napló |
Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T.
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Anticancer Drugs 1995 ; 6: 163-164. |
| 163 |
Napló |
Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA.
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
J Clin Pharm Ther 1994 ; 19: 127-133. |
| 169 |
Napló |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 174 |
Napló |
Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO.
Stability of esmolol hydrochloride in the presence of aminophylline, bretylium tosylate, heparin sodium, and procainamide hydrochloride.
Am J Hosp Pharm 1990 ; 47: 1567-1571. |
| 182 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 186 |
Napló |
Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
| 187 |
Napló |
Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.
Stability of flumazenil with selected drugs in 5% dextrose injection.
Am J Hosp Pharm 1993 ; 50: 1907-1912. |
| 198 |
Napló |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 214 |
Napló |
Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ.
Stability of ranitidine hydrochloride with eight medications in intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 1606-1610. |
| 215 |
Napló |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 240 |
Napló |
Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909. |
| 244 |
Napló |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Napló |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Napló |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Napló |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 257 |
Napló |
Hunt-Fugate AK, Hennessey CK, Kazarian CM.
Stability of fluconazole in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1186-1187. |
| 266 |
Napló |
Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 288 |
Napló |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 289 |
Napló |
Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707. |
| 295 |
Napló |
Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051. |
| 299 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Napló |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Napló |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 314 |
Napló |
Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65. |
| 315 |
Napló |
Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
| 317 |
Napló |
Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 334 |
Napló |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Napló |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 |
Napló |
Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 |
Napló |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 341 |
Napló |
Baker DE, Yost GS, Craig VL, Campbell RK.
Compatibility of heparin sodium and morphine sulfate.
Am J Hosp Pharm 1985 ; 42: 1352-1355. |
| 377 |
Napló |
Pereira-Rosario R, Utamura T, Perrin JH.
Interaction of heparin sodium and dopamine hydrochloride in admixtures studied by microcalorimetry.
Am J Hosp Pharm 1988 ; 45: 1350-1352. |
| 384 |
Napló |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632. |
| 386 |
Napló |
Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358. |
| 396 |
Napló |
Chilvers MR, Lysne JM.
Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.
Am J Hosp Pharm 1989 ; 46: 2057-2058. |
| 397 |
Napló |
Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126. |
| 398 |
Napló |
Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557. |
| 402 |
Napló |
Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821. |
| 406 |
Napló |
Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820. |
| 479 |
Napló |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 491 |
Napló |
Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184. |
| 492 |
Napló |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Napló |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 617 |
Napló |
Solomon DA, Nasinnyk KK.
Compatibility of haloperidol lactate and heparin sodium.
Am J Hosp Pharm 1982 ; 39: 843-844. |
| 660 |
Napló |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 738 |
Napló |
Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584. |
| 763 |
Napló |
Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326. |
| 791 |
Napló |
Hensrud DD, Buritt MF, Hall LG.
Stability of heparin anticoagulant activity over time in parenteral nutrition solutions.
JPEN 1996 ; 20: 219-220. |
| 813 |
Napló |
Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68. |
| 860 |
Napló |
Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028. |
| 874 |
Napló |
Stiles ML, Allen LV, Mc Laury HJ.
Stability of two concentrations of heparin sodium prefilled in CADD-Micro pump syringes.
Int J Pharm Compound 1997 ; 1: 433-434. |
| 891 |
Napló |
Matsuura G.
Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents.
Hosp Pharm 1992 ; 27: 200, 202, 209. |
| 895 |
Napló |
Yao JDC, Arkin CF, Karchmer AW.
Vancomycin stability in heparin and total parenteral nutrition solutions: novel approach to therapy of central venous catheter-related infections.
JPEN 1992 ; 16: 268-274. |
| 905 |
Napló |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Napló |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 939 |
Napló |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 963 |
Napló |
Schaaf LJ, Tremel LC, Wulf BG, Vernon KK.
Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside.
J Clin Pharm Ther 1990 ; 15: 371-376. |
| 1022 |
Napló |
Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886. |
| 1041 |
Napló |
Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951. |
| 1057 |
Napló |
Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1058 |
Napló |
Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.
Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.
Am J Hosp Pharm 1983 ; 40: 1690-1691. |
| 1067 |
Napló |
Zeidler C, Dettmering D, Schrammel W, Spieteller M.
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
EJHP 1999 ; 5: 106-110. |
| 1070 |
Napló |
Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891. |
| 1072 |
Napló |
Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
| 1084 |
Napló |
Raupp P, von Kriek R, Schmidt E, Pfahl HG, G?nther O.
Incompatibility between fat emulsion and calcium plus heparin in parenteral nutrition of premature babies.
Lancet 1988 ; 1(8587): 700. |
| 1085 |
Napló |
Irving HD, Burbridge BE.
Incompatibility of contrast agents with intravascular medications.
Radiology 1989 ; 173: 91-92. |
| 1135 |
Napló |
Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1183 |
Napló |
Tunbridge LJ, Lloyd JV, Penhall RK, Wise AL, Maloney T.
Stability of diluted heparin sodium stored in plastic syringes.
Am J Hosp Pharm 1981 ; 38: 1001-1004. |
| 1228 |
Napló |
Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381. |
| 1232 |
Napló |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1234 |
Napló |
Parkinson R, Wilson JV, Ross M, Denyer SP.
Stability of low-dosage heparin in pre-filled syringes.
Br J Pharm Pract 1989 ; 11: 34-36. |
| 1258 |
Napló |
Tyler LS, Rehder TL, Davis RB.
Effect of gentamicin on heparin activity.
Am J Hosp Pharm 1981 ; 38: 537-540. |
| 1289 |
Napló |
Hecq JD, Evrard JM, Gillet P, Grosdent N.
Etude de stabilité visuelle du chlorhydrate de chlorpromazine, du chlorure de potassium, de la furosémide et de l’héparine sodique en perfusion continue.
Pharmakon 1998 ; 116: 145-148. |
| 1291 |
Napló |
Wright A, Hecker J.
Long term stability of heparin in dextrose-saline intravenous fluids.
Int J Pharm Pract 1995 ; 3: 253-255. |
| 1315 |
Napló |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
| 1352 |
Napló |
Hasegawa GR, Eder JF.
Dobutamine-heparin mixture inadvisable.
Am J Hosp Pharm 1984 ; 41: 2588-2589. |
| 1391 |
Napló |
Vanstone GL.
Is heparin always compatible with TPN and fat emulsion admixtures?
Can J Hosp Pharm 1998 ; 51: 271-272. |
| 1393 |
Napló |
Lyall D, Blythe J.
Ciprofloxacin lactate infusion.
Pharm J 1987 ; 238: 290. |
| 1410 |
Napló |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1414 |
Napló |
Mayer JLR, Pascale VJ, Clyne LP, Malkus H, Santos FS, van Hoff J.
Stability of low-dose vancomycin hydrochloride in heparin sodium 100 UI / ml.
J Pharm Technol 1999 ; 15: 13-17. |
| 1415 |
Napló |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1420 |
Napló |
Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M.
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
J Clin Pharm Ther 1999 ; 24: 125-132. |
| 1423 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1468 |
Napló |
Sautou V, Chopineau J, Gremeau I, Chevrier R, Bruneaux F.
Compatibility with medical plastics and stability of continuously and simultaneously infused isosorbide dinitrate and heparin.
Int J Pharm 1994 ; 107: 111-119. |
| 1490 |
Napló |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1496 |
Napló |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1506 |
Napló |
Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112. |
| 1508 |
Napló |
Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124. |
| 1512 |
Laboratórium |
Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015 |
| 1625 |
Napló |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Napló |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1699 |
Napló |
Plaas S, Heck C, Kubrich M.
Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin.
Krankenhauspharmazie 2000 ; 21: 107-109. |
| 1703 |
Napló |
Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103. |
| 1712 |
Napló |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Napló |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Napló |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1754 |
Napló |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1801 |
Napló |
Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272. |
| 1802 |
Napló |
Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1803 |
Napló |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1822 |
Napló |
Trissel LA, Seanz C.
Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate.
Am J Health-Syst Pharm 2003 ; 60: 1650-1652. |
| 1868 |
Napló |
Husson E, Crauste-Manciet S, Hadj-Salah E, ,Segier JC, Broissard D.
Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange.
Nutr Clin Metab 2003 ; 17: 8-14. |
| 1906 |
Napló |
McQuade MS, Van Nostrand V, Shariter J, Kanike JD, Forsyth RJ.
Stability and compatibility of reconstituted ertapenem with commonly used iv infusion and coinfusion solutions.
Am J Health-Syst Pharm 2004 ; 61: 38-45. |
| 1925 |
Napló |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1937 |
Napló |
Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
| 1953 |
Napló |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1979 |
Napló |
Wu CC, Wang DP, Wong CY, Lin YF.
Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions.
Am J Health-Syst Pharm 2002 ; 59: 1537-1538. |
| 1982 |
Napló |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2037 |
Napló |
Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B.
Stability of heparin and physical compatibility of heparin/antibiotic solutions ...
J Antimicrob Chemother 2005 ; 56: 951-953. |
| 2057 |
Napló |
Droste JC, Jeraj HA, MacDonald A, Farrington K.
Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis.
J Antimicrob Chemother 2003 ; 51: 849-855. |
| 2087 |
Napló |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2090 |
Napló |
Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196. |
| 2100 |
Napló |
Gervas S, Gosalbez F.
Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100.
Farm Hosp 1995 ; 19: 38-40. |
| 2108 |
Napló |
Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232. |
| 2109 |
Napló |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2212 |
Laboratórium |
Reteplase (Rapilysin®) - Summary of Product Characteristics
Actavis UK Ltd 2015 |
| 2221 |
Napló |
Cober M.P, Johnson C.E.
Stability of 70% alcohol solutions in polypropylene syringes for use in ethanol-lock therapy.
Am J Health-Syst Pharm 2007 ; 64, 23: 2480-2482. |
| 2233 |
Napló |
Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
| 2247 |
Napló |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2262 |
Napló |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Napló |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2271 |
Laboratórium |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006 |
| 2279 |
Napló |
Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759. |
| 2335 |
Napló |
Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729 |
| 2346 |
Napló |
Newland A.M, Mauro V.F, Alexander K.S.
Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents
Am J Health-Syst Pharm 2009 ; 66: 986-987. |
| 2375 |
Napló |
Strong DK, Ho W, Nairn JG.
Visual compatibility of vancomycin and heparin in peritoneal dialysis solutions
Am J Hosp Pharm 1989 ; 46: 1832 - 1833. |
| 3012 |
Napló |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3125 |
Napló |
Baker D S, Waldrop Bruce, Arnold John.
Compatibility and Stability of Cefotaxine, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin.
Int J Pharm Compound 2010 ; 14, 4: 346-349. |
| 3134 |
Napló |
Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ; 21: 96-103. |
| 3152 |
Napló |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3176 |
Poszter |
Humbert Delaloye V, Berger M, Voirol P, Pannatier A.
Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.
16èmes JFSPH, Sion, 18-19 novembre 2010 |
| 3184 |
Laboratórium |
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005 |
| 3210 |
Napló |
Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261. |
| 3212 |
Napló |
Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.
Enferm Intensiva 2011 ;22:78-82. |
| 3216 |
Napló |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Napló |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Napló |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3267 |
Laboratórium |
Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011 |
| 3294 |
Napló |
Humbert-Delaloye V, Berger M, Voirol P, Pannatier A.
In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs
EJHP 2012 ; 19: 57-64. |
| 3327 |
Napló |
LaPlante K.L, Woodmansee S, Mermel L.A.
Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions.
Am J Health-Syst Pharm 2012 ; 69:1405-1409 |
| 3372 |
Napló |
Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166. |
| 3408 |
Napló |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3463 |
Napló |
Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R.
Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad.
Nursing 2011 ; 29 :62-6 |
| 3464 |
Napló |
Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau.
Compatibilidad física de la amiodarona en perfusión continua
Enferm Clin 2011 21:25-29. |
| 3465 |
Napló |
E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?.
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.
Enferm Intensiva 2010 ;21:96-103. |
| 3466 |
Napló |
B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau.
Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos
Enferm Intensiva 2011 ;22:78-82. |
| 3520 |
Laboratórium |
Cidomycin - Summary of product Chracteristics.
Sanofi 2011 |
| 3525 |
Laboratórium |
Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012 |
| 3529 |
Laboratórium |
Ciprofloxacin – Summary of Product Characteristics
Hospira 2013 |
| 3531 |
Laboratórium |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014 |
| 3540 |
Laboratórium |
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010 |
| 3548 |
Laboratórium |
Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007 |
| 3549 |
Laboratórium |
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3562 |
Laboratórium |
Ofloxacin (Tarivid®) - Summary of Product Characteristics
Sanofi 2014 |
| 3577 |
Laboratórium |
Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit
Galen Limited |
| 3580 |
Laboratórium |
Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016 |
| 3588 |
Laboratórium |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit
Sandoz 2011 |
| 3604 |
Laboratórium |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012 |
| 3605 |
Laboratórium |
Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010 |
| 3616 |
Laboratórium |
Altéplase (Actilyse®) - Résumé des caractéristiques du produit
Boehringer Ingelheim 2012 |
| 3617 |
Laboratórium |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011 |
| 3632 |
Laboratórium |
Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics
Hospira 2017 |
| 3637 |
Laboratórium |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3640 |
Laboratórium |
Mitoxantrone - Summary of Product Characteristics
Hospira 2013 |
| 3643 |
Laboratórium |
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015 |
| 3645 |
Laboratórium |
Doxorubicin - Summary of Product Characteristics
Accord Healthcare 2014 |
| 3665 |
Napló |
Ortega R, Salmer?n-Garc?a A, Cabeza J, Capit?n-Vallvey L.F, Navas N.
Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer’s injection and stored in polypropylene syringes at 4 and -20°C.
Am J Health-Syst Pharm 2014 ; 71:956-959 |
| 3674 |
Laboratórium |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3687 |
Laboratórium |
Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013 |
| 3728 |
Napló |
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
| 3766 |
Napló |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Napló |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3781 |
Napló |
Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A
Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide.
EJHP 2015 ;22:1 56-58 |
| 3823 |
Napló |
Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152. |
| 3824 |
Napló |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
Poszter |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
Poszter |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
Poszter |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3920 |
Laboratórium |
Levofloxacine - Résumé Caractéristique du Produit
Fresenius Kabi 2018 |
| 3923 |
Napló |
Luu Y, Thigpen J, Brown S.D.
Stability of sildenafil in combination with heparin and dopamine.
Am J Health-Syst Pharm 2017 ; 74, 1: e64-e71 |
| 3934 |
Laboratórium |
Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016 |
| 3956 |
Napló |
Bastani B; Amin K; Herr A.
Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique.
ASAIO Journal 2005 ; 51,6:761-763. |
| 3958 |
Napló |
Henrickson K.J; . Powell K.R; . Schwartz C.L.
A Dilute Solution of Vancomycin and Heparin Retains Antibacterial and Anticoagulant Activities .
J Infect Dis 1988 ; 157, 3: 600-601. |
| 3964 |
Napló |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 3976 |
Napló |
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
| 4055 |
Napló |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4056 |
Napló |
Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R.
Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions.
Perit Dial Int 2017 |
| 4108 |
Napló |
Cruz K, Chrchwell M, Mauro V, Boddu.
Physical compatibility of levetiracetam injection with heparin, dobutamine, and dopamine.
Am J Health-Syst Pharm 2018 ;75;8:510-512 |
| 4145 |
Napló |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4166 |
Napló |
Bowie H.M, Haylor V.
Stability of heparin in sodium chloride solution.
J Clin Pharm Ther 1978 3:211-214 |
| 4180 |
Napló |
Mendes K, Harmanjeet H, Sedeeq M, Modi A, Wanandy T, Zaidi S, Ming L, Castelino R, Sud K, Peterson G, Patel R.
Stability of meropenem and piperacillin/tazobactam with heparin in various peritoneal dialysis solutions.
Perit Dial Int 2018 ;38,6:430-440 |
| 4254 |
Napló |
D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40 |
| 4319 |
Napló |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4332 |
Poszter |
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI)
Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI).
JFSPH 2019 2019 |
| 4389 |
Napló |
Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213 |
| 4419 |
Napló |
Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161. |
| 4433 |
Napló |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4434 |
Napló |
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170. |
| 4491 |
Napló |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2020 |
| 4507 |
Napló |
Ross E, Salinas A, Petty K, Her C, Carpenter J.
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Am J Health-Syst Pharm 2020 ;77,23:1980-1985 |
| 4528 |
Napló |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4538 |
Napló |
Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397. |
| 4556 |
Napló |
Dobson, S.R, Mauro, V.F, Boddu, S.H.S, Churchwell, M.D.
The Physical Compatibility of Clinically Used Concentrations of Diltiazem Hydrochloride With Heparin Sodium.
J Pharm Technol 2020 ; 36, 4: 126-129. |
| 4603 |
Napló |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4612 |
Napló |
Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E.
Estabilidad de la solución de gentamicina y heparina para sellado de catéter.
OFIL 2014 24;2:86-90 |
| 4651 |
Napló |
De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A.
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
Eur J Pedia 2021 ;180,1169–1176. |
| 4654 |
Poszter |
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021 |
| 4698 |
Napló |
Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022 |
| 4724 |
Napló |
Maktabi B, Howard MS, Baki G, Churchwell MD
Intravenous Physical Compatibility of Heparin Sodium and Furosemide.
Int J Pharm Compound 2022 ;26,6:522-526 |
| 4732 |
Napló |
Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E.
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
Am J Health-Syst Pharm 2023 80, 3;164–170 |
| 4742 |
Napló |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4768 |
Napló |
Kondo M, Genpei M, Watanabe K, Yoshida M, Tagui N, Fukao S, Sugaya K, Takase H.
Y-site injection physical compatibility of remdesivr with select intravenous drugs used in palliative care and for treating coronavirus disease 2019.
Journal of Nippon Medical school 2023 |
